Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, Ding YS, Adam M, Aasly J, Wszolek ZK, Farrer M, Sossi V, Stoessl AJ. Wile DJ, et al. Among authors: aasly j. Lancet Neurol. 2017 May;16(5):351-359. doi: 10.1016/S1474-4422(17)30056-X. Epub 2017 Mar 20. Lancet Neurol. 2017. PMID: 28336296 Free PMC article.
Linkage disequilibrium and association of MAPT H1 in Parkinson disease.
Skipper L, Wilkes K, Toft M, Baker M, Lincoln S, Hulihan M, Ross OA, Hutton M, Aasly J, Farrer M. Skipper L, et al. Among authors: aasly j. Am J Hum Genet. 2004 Oct;75(4):669-77. doi: 10.1086/424492. Epub 2004 Aug 3. Am J Hum Genet. 2004. PMID: 15297935 Free PMC article.
Parkinsonism, FXTAS, and FMR1 premutations.
Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ. Toft M, et al. Among authors: aasly j. Mov Disord. 2005 Feb;20(2):230-3. doi: 10.1002/mds.20297. Mov Disord. 2005. PMID: 15390127
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.
Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Kachergus J, et al. Among authors: aasly j. Am J Hum Genet. 2005 Apr;76(4):672-80. doi: 10.1086/429256. Epub 2005 Feb 22. Am J Hum Genet. 2005. PMID: 15726496 Free PMC article.
LRRK2 mutations are not common in Alzheimer's disease.
Toft M, Sando SB, Melquist S, Ross OA, White LR, Aasly JO, Farrer MJ. Toft M, et al. Among authors: aasly jo. Mech Ageing Dev. 2005 Nov;126(11):1201-5. doi: 10.1016/j.mad.2005.06.010. Mech Ageing Dev. 2005. PMID: 16087219
Lrrk2 pathogenic substitutions in Parkinson's disease.
Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. Mata IF, et al. Among authors: aasly j. Neurogenetics. 2005 Dec;6(4):171-7. doi: 10.1007/s10048-005-0005-1. Epub 2005 Sep 17. Neurogenetics. 2005. PMID: 16172858
PINK1 mutation heterozygosity and the risk of Parkinson's disease.
Toft M, Myhre R, Pielsticker L, White LR, Aasly JO, Farrer MJ. Toft M, et al. Among authors: aasly jo. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):82-4. doi: 10.1136/jnnp.2006.097840. J Neurol Neurosurg Psychiatry. 2007. PMID: 17172567 Free PMC article.
Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease.
Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ. Toft M, et al. Among authors: aasly jo. Mov Disord. 2007 Feb 15;22(3):389-92. doi: 10.1002/mds.21217. Mov Disord. 2007. PMID: 17216639
267 results